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Factors associated with SARS fatality
Background/Purpose: Severe acute respiratory syndrome (SARS) has a high fatality rate worldwide. We
examined the epidemiologic and clinical factors associated with death for all laboratory-confirmed SARS
patients in Taiwan.
Methods: Using initial data in medical records reported by hospitals to the Center for Disease Control in
Taiwan, we analyzed whether hematological, biochemical and arterial blood gas measures could predict
fatality in 346 SARS patients.
Results: Both fatalities (n = 73; 21.1%) and survivors had elevated plasma concentration of initial C-reactive
protein (CRP), but the mean CRP concentration was higher in fatalities (47.7 ± 43.3 mg/L) than in survivors
(24.6 ± 28.2 mg/L). Initial lymphocyte counts were low in both fatalities (814 ± 378/μL) and survivors
(1019 ± 480/μL). After controlling for age and sex, multiple logistic regression analysis showed that
hematological factors significantly associated with fatality included initial neutrophil count > 7000/μL
(odds ratio [OR] = 6.4), initial CRP concentration > 47.5 mg/L (OR = 5.8) and lactic acid dehydrogenase
(LDH) > 593.5 IU/L (OR = 4.2). Factors significantly associated with initial CRP concentration > 47.5 mg/L
included dyspnea (OR = 4.3), red blood cell count < 4.1 × 106/μL (OR = 4.3) and serum aspartate amino-
transferase > 57 IU/L (OR = 3.1).
Conclusion: Initial neutrophil count, CRP and LDH levels are important predictors of mortality from SARS.
[J Formos Med Assoc 2006;105(6):439–450]
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Severe acute respiratory syndrome (SARS) is an
emerging respiratory infectious disease which first
appeared in Guangdong, China in November 2002.
The disease spread concurrently to Vietnam, Hong
Kong, Canada, Singapore and Taiwan in February
2003 and later throughout the world,1–3 and was
controlled rapidly in a few months with a peak in
April 2003 in Taiwan. During the epidemic, a to-
tal of 8422 probable SARS patients were reported
to the World Health Organization (WHO) from
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32 countries, with an estimated case fatality rate
of 10.9% (n = 916) from November 1, 2002 to
August 7, 2003.4
Patients in the early stages of SARS generally
suffered from fever, malaise, myalgia, dyspnea,
headache, nonproductive cough, chills and short-
ness of breath.5–18 A few patients had upper respi-
ratory tract symptoms such as sore throat and
rhinorrhea. Diarrhea, nausea and vomiting were
also reported. Studies also reported the presence
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hospitals that had cared for SARS patients during
the outbreak in Taiwan) 10 days prior to the onset
of symptoms. On August 14, 2003, the WHO pro-
posed a new case definition as clinical cases with
positive laboratory findings for SARS-CoV based
on one or more of the diagnostic criteria, includ-
ing reverse transcriptase polymerase chain reaction
(RT-PCR), seroconversion or virus isolation.24 This
study included all 346 cases from Taiwan who met
the revised WHO criteria.
Data collection
All hospitals that had cared for SARS patients re-
ported patient medical records to the Center for
Disease Control of the Taiwan Department of
Health. Data available included initial clinical
symptoms, and hematological, biochemical and
arterial blood gas measures at admission. In
addition, we obtained information on sociodemo-
graphic characteristics, contacts prior to the onset
of illness, date of diagnosis of the disease, survival
status, and cause of death.
Statistical analysis
The contact history of patients and epidemic curve
of fatalities and survivals of SARS patients were
depicted graphically. This study emphasized the
identifying factors considered most likely to pre-
dict death from SARS and the comparison between
fatalities and survivors of the disease. Prior to per-
forming this analysis, however, the clinical symp-
toms and laboratory manifestations of positive and
negative cases were compared and briefly summa-
rized in the results.
The case fatality rate was determined based on
all SARS cases according to the WHO definition
and irrespective of immediate causes of death. The
chi-square test was used to explore differences in
demographic characteristics, clinical symptoms
and comorbidity, while the t test was used to iden-
tify proportional differences in clinical laboratory
manifestations. Mean values ± standard deviations
(SD) of initial hematological and biochemical vari-
ables and arterial blood gas were also compared
between fatalities and survivors and against nor-
mal ranges of these measures.25 Each potential risk
of high rates of comorbidities in SARS patients,
particularly diabetes mellitus (DM), cardiac disease
or hypertension.5–7,12,19,20 Laboratory findings for
SARS patients included lymphopenia, and ele-
vated lactic acid dehydrogenase (LDH), hepatic
transaminase, creatine phosphokinase (CPK), and
hepatic transaminases.5,7–13,16,21,22 White blood cell
(WBC) counts and renal function remained
normal.15 However, only age (advanced or > 60
years), shortness of breath, comorbidity (DM, car-
diac or other diseases), elevated neutrophil count
and LDH were independent predictors of death
from SARS.5,7,13,16,20–22 Singh et al found elevated
levels of initial C-reactive protein (CRP) in SARS
patients.12 Wang et al also reported a high pre-
valence of lymphopenia (< 1 × 109/L, 64.5%) and
elevated CRP levels (> 8.0 mg/L, 77.9%) in SARS
patients treated at a medical center in Northern
Taiwan.22
Using a comparison design, we examined the
epidemiologic and clinical patterns of death for
all reported SARS patients in Taiwan. The main
focus of this study was to compare the laboratory
features between fatalities and survivors and to es-
timate the risk of death based on initial hemato-
logical and biochemical measures and arterial
blood gas characteristics. We also attempted to
determine if the elevated initial CRP concentration
in SARS patients was associated with other clinical
and laboratory parameters.
Methods
Patients
In accordance with the WHO criteria published in
May 2003,23 and modified for Taiwan, 664 people
were initially diagnosed as probable SARS cases,
presenting with a history of fever of 38°C or above,
symptom(s) of lower respiratory tract illness, ra-
diographic evidence of infiltrates consistent with
pneumonia, respiratory distress syndrome or au-
topsy findings consistent with pneumonia with-
out identifiable cause, and with exposure such as
close contact with a suspected or probable case of
SARS and/or residing in an affected area (including
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factor for death was first estimated with odds ra-
tio (OR) and corresponding 95% confidence in-
terval (CI) using univariate logistic regression.
All variables were categorized. The normal ranges
of hematological and biochemical determinations
were not consistent among hospitals. However, in
order to facilitate comparison of factors associated
with risk of fatality, quartile values were adapted
to determine the associated OR of death based on
univariate analyses.
Because SARS was characterized by inflamma-
tion in most patients, this study also emphasized
identification of factors associated with CRP level
among patients. The percentile distributions of in-
itial CRP concentrations were compared with ma-
jor comorbidities, such as DM, cardiac disease,
chronic obstructive pulmonary disease (COPD),
cerebrovascular accident (CVA) and malignancy.
Mean concentrations and SD were calculated as
well. The risk of elevated initial CRP for each po-
tentially associated factor was estimated with OR
and corresponding 95% CI with all variables cate-
gorized. Consideration of various CRP cut-off val-
ues revealed that more variables were significantly
associated with CRP at the cut-off value of 47.5
mg/L (75th percentile) than 5 mg/L (normal value)
or 29.1 mg/L (mean value).
When a variable had upper and/or low quartile
values beyond the normal range, the 75th percen-
tile value was used for the estimation of positive
correlation, and the 25th percentile value for nega-
tive correlation. Otherwise, the normal value was
used to determine the cut-off value.
Hematological, biochemical and arterial blood
gas data were based on the initial measures avail-
able from the reported records provided by hos-
pitals. Variables with a p value of less than 0.05 in
the univariate analyses were included in the down-
ward stepwise multiple logistic regression analyses.
Sex, age, DM and neutrophil count were forced in
the multiple logistic regression analysis because
of potential confounding effects, although sex be-
came an insignificant factor in doing so. Data anal-
yses were performed using SAS version 8.0 (SAS
Institute Inc, Cary, NC, USA). Sex and age were
forced in the adjusted model.
Results
Study population
A total of 664 probable SARS cases had been
reported by the time the WHO officially removed
Taiwan from the list of SARS-affected areas in
July 2003.3 Among them, 346 cases were later
confirmed by serological tests (either PCR or Ab
positive) based on WHO criteria announced in
August 200324 (Figure). The epidemic curve shows
that almost all fatal cases occurred between April
16 and June 7, 2003, while the incidence showed
a bimodal pattern in the week of April 21 and the
week of May 11.
Figure. Epidemiologic curve of SARS fatalities and survivors by date of onset in Taiwan, February 24 to July 15, 2003.
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The confirmed positive SARS cases (n = 346)
were younger (42.3 vs. 53.0 years old) and in-
cluded more females (63.0% vs. 40.9%) than the
SARS-negative cases (n = 318) (data not shown).
Symptomatic signs at presentation showed that
positive cases were more likely than negative cases
to have chills, diarrhea and myalgia but less likely
to have increased sputum production, cough, dys-
pnea and shortness of breath. Comorbidity was
more prevalent in negative than in positive cases
(29.2% vs. 17.1%), particularly in patients with
COPD and malignancy. Negative cases had higher
mean counts than positive cases for white blood
cells (WBC), neutrophils, lymphocytes, monocytes
and platelets and blood urea nitrogen (BUN).
However, CRP was higher in positive cases.
Characteristics of fatalities and survivors
The overall case fatality rate was 21.1% (n = 73),
and increased from 7.2% for patients younger
than 40 years to 58.9% for those aged 60 years
or older (p < 0.0001) (Table 1). This outbreak in-
volved 105 healthcare employees, who were less
likely than non-healthcare persons to die from the
disease (11.4% vs. 25.3%). An increased risk was
also found for men (30.5%) and patients with hos-
pital contact (26.3%). All imported cases survived.
Clinical characteristics
SARS fatalities had a higher rate of intubation
(Table 2). Analysis of symptomatic signs showed
that fatalities were more likely than survivors to
have dyspnea (41.1% vs. 17.2%), but less likely to
have headache and rhinorrhea. Comorbidity was
also more prevalent in fatalities than in survivors
(48.0% vs. 8.8%, p < 0.0001), particularly DM,
COPD and CVA.
Table 3 compares the mean values of initial
hematological and biochemical measures and
arterial blood gas between fatalities and survivors
Table 1. Comparison of demographic characteristics and contact history between fatalities and
survivors in SARS patients in Taiwan
Variable
Fatalities (n = 73) Survivors (n = 273) Total (n = 346)
p*
n (%) n (%) n (%)
Age, mean (SD)† 57.5 (17.6)0. 38.2 (14.9).0 42.3 (17.4)0. < 0.0001
Age, yr < 0.0001
< 40 12 (7.2)0 155 (92.8)0 167 (100)0
40–59 28 (22.8) 95 (77.2) 123 (100)0
* 60 33 (58.9) 23 (41.1) 56 (100)
Sex 0.001
Female 34 (15.6) 184 (84.4)0 218 (100)0
Male 39 (30.5) 89 (69.5) 128 (100)0
Occupation 0.004
Healthcare worker 12 (11.4) 93 (88.4) 105 (100)0
00Physician 1 11 12
00Nurse 2 54 56
00Allied 9 28 37
Non-healthcare worker 61 (25.3) 180 (74.7)0 241 (100)
Contact history 0.002
Imported 0 (0.0) .21 (100)0 21 (100)
Household 3 (7.7) 36 (92.3) 39 (100)
Hospital 65 (26.3) 182 (73.7)0 247 (100)0
Unidentified 05 (12.8) 34 (87.2) 39 (100)
*Chi-square test or Fisher’s exact test; †mean and standard deviation (SD) by t test.
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and against normal ranges.25 Parameters with
means exceeding the normal range were blood
sugar, BUN, LDH, CRP, and serum aspartate ami-
notransferase (AST). These values were all signifi-
cantly higher for fatalities than for survivors. The
initial lymphocyte count was significantly lower
in fatalities than in survivors (814/μL vs. 1019/μL,
p = 0.004). Initial mean counts of WBC, neu-
trophils and monocytes were significantly higher
in fatalities than in survivors. The mean counts of
WBC, neutrophils and monocytes, however, were
in the normal range.
Factors associated with death
Variables with p < 0.05 in the univariate analyses
were entered into the multiple logistic regression
model with sex and age forced in the model. Men
were at higher risk of death than women in the
univariate analysis, but not in the final multiple
logistic regression analysis (Table 4). Age was a
significant factor associated with death together
with dyspnea, DM, hematological and biochemi-
cal measures in the model. Patients * 60 years old
had the highest risk of death (OR = 12.4; 95% CI =
1.8, 83.3). Neutrophil count > 7000/μL was also
Table 2. Comparison of clinical features and comorbidity between fatalities and survivors in SARS
patients in Taiwan
Characteristic
Fatalities (n = 73) Survivors (n = 273)
p*
n (%) n (%)
Intubation 19 (26.0) 22 (8.1)0 < 0.0001
Initial clinical symptom
Fever 073 (100.0) .273 (100.0)
Cough 45 (61.6) 163 (59.7)0 0.764
Dyspnea 30 (41.1) 47 (17.2) < 0.0001
Diarrhea 23 (31.5) 63 (23.1) 0.139
Shortness of breath 4 (5.5) 12 (4.4)0 0.695
Sputum production 14 (19.2) 34 (12.5) 0.140
Chills 09 (12.3) 47 (17.2) 0.314
Myalgia 12 (16.4) 55 (20.2) 0.476
Sore throat 7 (9.6) 40 (14.7) 0.262
Vomiting 6 (8.2) 12 (4.4)0 0.191
Headache 6 (8.2) 50 (18.3) 0.038
Chest pain 3 (4.1) 10 (3.7)0 0.741
Abdominal pain 3 (4.1) 13 (4.8)0 1.000
Nausea 3 (4.1) 11 (4.0)0 1.000
Rhinorrhea 0 (0.0) 15 (5.5)0 0.048
Comorbidity
Diabetes mellitus 18 (25.7) 12 (4.5)0 < 0.0001
Cardiac disease 13 (18.6) 6 (2.2) < 0.0001
Chronic obstructive pulmonary disease 09 (12.9) 5 (1.9) < 0.0001
Hypertension 12 (17.1) 11 (4.1)0 0.0001
Malignancy 1 (1.4) 2 (0.7) 0.502
Cerebrovascular accident 08 (11.4) 4 (1.5) < 0.0001
End-stage renal disease 1 (1.4) 2 (0.7) 0.502
Immunologic disease 2 (2.9) 0 (0.0) 0.042
Liver disorder 0 (0.0) 2 (0.7) 1.000
Coexisting medical disease† 35 (48.0) 24 (8.8)0 < 0.0001
*Chi-square test or Fisher’s exact test; †includes any one of following diseases: diabetes mellitus, cardiac disease, chronic obstructive
pulmonary disease, hypertension, malignancy, cerebrovascular accident, end-stage renal disease, immunologic disease and liver disorder.
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Table 3. Comparison of initial laboratory tests between fatalities and survivors in SARS patients in
Taiwan
Fatalities Survivors p
Normal range
Mean (SD) Mean (SD) (t test)
Hematological variables
WBC (/μL) 08312 (4509) 6084 (3092) < 0.0001. 0,4500–11,000
Neutrophils (/μL) 06554 (3750) 4608 (2874) < 0.0001. 3000–7000
Lymphocytes (/μL) 0814 (378) 1019 (480)0 0.004 1500–4000
Monocytes (/μL) 0473 (306) 354 (210) 0.001 100–500
Platelets (103/μL) 190.6 (95.7) 171.6 (68.6)0 0.070 140–380
RBC (106/μL) 04.4 (0.4) 4.4 (0.6) 0.625 4.5–6.2
Hemoglobin (g/dL) 12.9 (1.9) 13.0 (1.8)0 0.674 13.5–18.0
Mean cell volume (fL) 87.1 (8.6) 86.5 (9.2)0 0.675 080–100
Biochemical variables
Sugar (mg/dL) 0181.9 (101.5) 119.4 (45.9)0 00.0003 070–105
BUN (mg/dL) 023.5 (22.7) 11.4 (9.0)0 < 0.0001. 06–20
CPK (IU/L) 0297.5 (758.3) 159.7 (385.8) 0.117 015–130
LDH (IU/L) 0583.9 (514.1) 435.9 (317.4) 0.020 180–460
CRP (mg/L) 047.7 (43.3) 24.6 (28.2) 00.0001 < 5
AST (IU/L) 0077.3 (102.8) 43.7 (43.3) 0.002 10–30
ALT (IU/L) 045.4 (54.2) 36.9 (39.5) 0.211 06–35
Na (mmol/L) 136.7 (5.1)0 137.5 (3.6)00 0.183 137–145
K (mmol/L) 04.0 (0.9) 4.0 (0.5) 0.554 3.5–5.0
Arterial blood gas
pH 07.42 (0.11) 7.44 (0.07) 0.417 7.31–7.45
pCO2 (mmHg) 33.5 (6.2) 33.8 (5.2)0 0.809 35–46
pO2 (mmHg) 079.2 (36.7) 89.6 (21.2) 0.087 090–104
O2SAT (%) 091.6 (13.5) 96.1 (3.0)0 0.131 95–98
WBC = white blood cells; RBC = red blood cells; BUN = blood urea nitrogen; CPK = creatine phosphokinase; LDH = lactic acid
dehydrogenase; CRP = C-reactive protein; AST = aspartate aminotransferase; ALT = alanine aminotransferase; Na = sodium; K =
potassium; pCO2 = partial carbon dioxide pressure; pO2 = partial oxygen pressure; O2SAT = blood oxygen saturation rate.
Table 4. Factors predicting death from SARS using a multiple logistic regression model for patients in
Taiwan
Variable OR 95% CI p Normal range
Age, yr
< 40 1.0
40–59 5.0 1.0–25.4 0.054
* 60 12.4 1.8–83.3 0.010
Sex (male) 1.0 0.1–2.50 0.488
Dyspnea 1.9 0.5–8.20 0.376
Diabetes mellitus (yes/no) 5.2 0.9–28.3 0.058
Neutrophils (> 7000/μL) 6.4 1.1–36.0 0.034 3000–7000
Lymphocytes (< 700/μL) 3.9 1.0–15.8 0.053 1500–4000
LDH (> 593.5 IU/L) 4.2 1.0–17.3 0.048 180–460
CRP (> 47.5 mg/L) 5.8 1.5–23.0 0.013 < 5
OR = odds ratio; CI = confidence interval; LDH = lactic acid dehydrogenase; CRP = C-reactive protein.
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independently associated with death (OR = 6.4;
95% CI = 1.1, 36.0). Initial biochemical measures
of the highest quartiles significant for death were
CRP > 47.5 mg/L (OR = 5.8; 95% CI = 1.5, 23.0)
and LDH > 593.5 IU/L (OR = 4.2; 95% CI = 1.0,
17.3).
Concentration of plasma CRP in SARS patients
Patients with (n = 211) and without (n = 135) CRP
tests had similar distributions of age, sex, oc-
cupation, contact history, intubation status and
fatality (data not shown). There were also no sig-
nificant differences between these two groups
for most variables of symptoms and comorbidi-
ties, except that patients who had CRP tests had a
higher prevalence of myalgia (24.6% vs. 11.1%,
p = 0.002), hypertension (9.0% vs. 3.0%, p =
0.043), but a lower prevalence of cough (55% vs.
68.1%, p = 0.015).
Approximately 69.9% of patients with CRP
tests had initial levels greater than the normal val-
ue of 5 mg/L, and women had lower values than
men (median: 10.4 vs. 25.3 mg/L). In general, CRP
concentrations in SARS patients were lower for
young patients than for old patients. The overall
mean CRP level was 29.1 mg/L (SD = 32.9 mg/L),
the median was 12.6 mg/L, the 75th percentile val-
ue for those with comorbidity was 83.3 mg/L and
for those without comorbidity was 34.3 mg/L
(Table 5). Patients with COPD, CVA and cardiac
disease had higher mean CRP (all approximately
61.5 mg/L).
Factors associated with elevated initial CRP
Factors significantly associated with CRP > 47.5
mg/L in the univariate analyses were old age, male
gender, non-healthcare worker, fatal cases, and
patients with dyspnea, DM, COPD, cardiac disease,
hypertension, CVA, lymphocyte count < 700/μL,
red blood cell (RBC) < 4.1 × 106/μL, creatine phos-
phokinase (CPK) > 158 IU/L, LDH > 593.5 IU/L,
serum AST > 57 IU/L, serum alanine aminotrans-
ferase (ALT) > 42 IU/L, partial pressure of dioxide
< 71.7 mmHg and oxygen saturation < 93.9%, etc.
Since CRP likely changed during the different clin-
ical stages and patients were admitted in different
clinical stages, the day on which initial CRP was
measured, which was counted from the first day
of fever, should be very important. The univariate
analysis, however, found no significant association
between elevated CRP and the time of measure-
ment after fever onset. But after controlling for age
and sex in the stepwise multiple logistic regression
model, an elevated initial CRP level > 47.5 mg/L
had a significant positive association with dysp-
nea (OR = 4.3; 95% CI = 1.7–11.2), lower RBC
(OR = 4.3; 95% CI = 1.6–11.4), and elevated AST
(OR = 3.1; 95% CI = 1.3–7.6) (Table 6).
Since dyspnea is an important symptom for
SARS patients, we also assessed the association
Table 5. Percentile distribution and average plasma C-reactive protein levels by comorbidity
Comorbidity n
C-reactive protein (mg/L)
Mean ± SD
100% 75% 50% 25% 0%
Diabetes mellitus 20 120.0 81.9 31.5 05.8 1.5 42.5 ± 39.7
Cardiac disease 11 128.0 86.4 56.4 10.0 4.7 61.4 ± 42.5
COPD 06 128.0 80.4 73.4 08.3 5.7 61.5 ± 47.0
Hypertension 19 128.0 83.3 51.0 12.0 3.8 54.3 ± 42.1
Cerebrovascular accident 10 120.0 92.4 61.9 38.4 4.7 61.5 ± 36.6
Other comorbidity* 09 128.0 85.0 15.2 11.1 8.3 49.7 ± 49.6
Subtotal (A) 39 128.0 83.3 51.0 10.0 1.5 49.0 ± 40.8
No comorbidity (B) 1720 159.0 34.3 11.4 04.0 0.0 24.6 ± 29.1
Total (A+B) 2110 159.0 47.5 12.6 04.6 0.0 29.1 ± 32.9
*Includes any one of the following diseases: malignancy, end-stage renal disease, immunologic disease, liver disorder. SD = standard deviation;
COPD = chronic obstructive pulmonary disease.
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of dyspnea with initial CRP level. The mean ±
SD CRP level was 52.2 ± 44.8 mg/L for patients
with dyspnea and 23.8 ± 27.1 mg/L for patients
without dyspnea (Table 7). The age-sex-adjusted
OR in patients with CRP levels > 47.5 mg/L
were 6.0 (95% CI = 1.8–20.3) for fatalities with
dyspnea, 3.5 (95% CI = 1.3–9.0) for survivors with
dyspnea, and 2.8 (95% CI = 1.0–7.4) for fatalities
without dyspnea compared to survivors without
dyspnea.
Discussion
This study found that sex, age, occupation and con-
tact history were significantly associated with SARS
fatality in univariate analyses. These associations
disappeared, however, when dyspnea, neutrophil
count, lymphocyte count, LDH or CRP were add-
ed to bivariate analyses, except for the association
with age, which remained significant. Age * 60
years, initial neutrophil count, CRP level and LDH
level were significant predictors of death from
SARS. Compared to survivors without dyspnea,
the age-sex-adjusted OR in patients with initial
CRP levels > 47.5 mg/L were 6.0 for fatalities with
dyspnea, 3.5 for survivors with dyspnea, and 2.8
for fatalities without dyspnea. Therefore, initial
CRP is not only a marker associated with SARS
progression, but can also be used to predict the
severity of this coronavirus infection.
The present study of 346 cases showed that
the fatality rate was much greater for patients
with comorbidity (59.3% or 35/59) than for those
without comorbidity (13.2% or 38/287). For the
41 patients with endotracheal intubation, the
case fatality rate was 46.3% (19/41). The overall
case fatality rate from SARS in Taiwan was slightly
Table 6. Factors predicting plasma C-reactive protein level > 47.5 mg/L in SARS patients using a
multiple logistic regression model
Risk factor OR 95% CI p Normal range
Age, yr
< 40 1.0
40–59 1.0 0.4–2.5 0.965
* 60 1.3 0.4–4.5 0.671
Sex (male) 2.3 1.0–5.7 0.063
Dyspnea 4.3 1.7–11.2 0.003
Comorbidity (yes/no)* 2.5 0.9–7.4 0.093
RBC (< 4.1 × 106/μL) 4.3 1.6–11.4 0.003 4.5–6.2
AST (> 57 IU/L) 3.1 1.3–7.6 0.011 10–30
*Includes any one of the following diseases: diabetes mellitus, cardiac disease, chronic obstructive pulmonary disease, hypertension,
malignancy, cerebrovascular accident, end-stage renal disease, immunologic disease, liver disorder. OR = odds ratio; CI = confidence
interval; RBC = red blood cells; AST = aspartate aminotransferase.
Table 7. C-reactive protein (CRP) levels for SARS fatalities and survivors by dyspnea status and
age-sex-adjusted odds ratios of having CRP > 47.5 mg/L
Dyspnea Death n Mean ± SD (mg/L) OR (95% CI) p
Yes 52.2 ± 44.8
Yes 15 64.6 ± 51.8 06.0 (1.8, 20.3) 0.004
No 24 44.5 ± 38.9 3.5 (1.3, 9.0) 0.010
No 23.8 ± 27.1
Yes 26 38.0 ± 35.1 2.8 (1.0, 7.4) 0.046
No 1460 21.3 ± 24.7 1.0
SD = standard deviation; OR = odds ratio; CI = confidence interval.
447J Formos Med Assoc | 2006 • Vol 105 • No 6
Factors associated with SARS fatality
higher than that in a medical center reported by
Wang et al,22 but much higher than the WHO re-
ported average fatality rates of 10.9% worldwide,
14% in Singapore and 16% in Canada.4 The high
proportion of hospital-associated infection during
the outbreak period may explain the elevated fa-
tality rate, particularly involving inpatients, as sup-
ported by the high comorbidity rate in the study
patients.
Comparison of vital signs, clinical symptoms
and comorbidity between fatalities and survivors
revealed that initial hematological and biochemi-
cal characteristics may be attributable to the risk
of fatality from SARS. This study had the advan-
tage that hospitals were required to report these
initial data for all potential SARS patients to the
government health authority. In previous studies,
comorbidity, particularly DM and cardiac disease,
was significantly associated with higher risk of
death from SARS.5,7,13,22 Although we found simi-
lar patterns in the univariate analysis, only DM re-
mained significant in the multivariate analysis. This
is attributable to the predicative value of initial
neutrophil count (> 7000/μL), LDH level (> 593.5
IU/L) and CRP level (> 47.5 mg/L) for fatality from
SARS. Previous studies also found a significant as-
sociation between death and high levels of initial
LDH5,7,13,16,20–22 and CRP.12,22 Death is thus more
likely to occur in patients with these conditions.
Consistent with previous studies, we found that
older patients were more likely to have higher LDH
and neutrophil count.5,7,16,20,21
Both CRP and LDH are markers of inflam-
mation. Initial LDH level was also an independ-
ent predictor of death in this study, but not in the
study of Wang et al.22 Our study included a na-
tionwide sample of a much larger size than their
single hospital study. Previous studies found strong
evidence of an elevated risk for developing adverse
outcomes or acute respiratory distress syndrome
in SARS patients from Hong Kong with elevated
LDH.16,20,21 In agreement with these studies, we
found that a high serum LDH level appeared to
be associated with increased mortality in SARS
cases in the multivariate analysis. This finding is
also similar to results of studies in patients with
Pneumocystis carinii pneumonia and AIDS.26,27 In-
creased serum LDH has also previously been as-
sociated with several pulmonary infections, includ-
ing tuberculosis and bacterial pneumonia.28,29
Several comorbidity variables were significant
factors in the prediction of SARS fatality in the
univariate analyses of this study. However, only
DM remained significant when dyspnea was add-
ed to the model. The initial association of CRP
with fatality was consistent with the findings of
Singh et al12 and Wang et al.22 Singh et al’s study in
Singapore found that 7 of 11 SARS patients had
elevated CRP with a higher proportion in fatalities
than in survivors (75% vs. 25%).12 Wang et al’s
study at a medical center also found that 77.9%
(53/68) of SARS patients with elevated initial
CRP were at higher risk of fatality (OR = 1.447 for
every 1 mg/dL increase, p = 0.006).22 We also found
that elevated initial CRP was a factor associated
with higher OR of deaths for all SARS patients in
Taiwan. The present study had a greater sample
size than previous studies from Taiwan, with ini-
tial CRP test results available for 211 of 346 SARS
patients.
CRP is one of the most sensitive acute-phase
reactants and is virtually absent from blood serum
in the healthy person. CRP levels can increase
dramatically after bacterial and viral infections,
inflammation and severe trauma.25 Higher blood
CRP level plays an instructive role in the acquired
immune response as innate recognition lectin,30 a
pentameric polypeptide initially reported in pa-
tients with Streptococcus pneumonia.31 Furthermore,
this nonspecific inflammation marker may pre-
dict the risk of cardiovascular events and hyper-
tension development.32–34 In the present study, we
found that SARS patients with the comorbidities
of cardiac disease, hypertension and CVA had high
plasma CRP concentrations and were at high risk
of fatality. This risk, however, was not as great as
that of patients with the comorbidity of DM. High
CRP has also been associated with acute dyspnea
due to bacterial pneumonia and bronchitis.35 Dys-
pnea was an important variable in predicting CRP
level. Neutrophil and lymphocyte counts, BUN and
CPK were significant predictors of CRP level in the
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univariate analysis. These associations became
insignificant, however, when dyspnea was added
into the model in the bivariate analysis.
In this study, the initial serum samples for he-
matological and biochemical tests were collected
an average of 3.1 days and 3.4 days after the onset
of illness (median, 2 days). The mean initial CRP
level was lower for the 191 cases with blood speci-
mens collected in the first week than for the 18
cases with specimens collected in the second
week after the onset of disease (mean ± SD: 27.6 ±
32.4 vs. 41.0 ± 36.7 mg/L). In other words, the
CRP levels may increase to approximately 28
mg/L within 1 week after the disease is noted. The
typical CRP concentration is < 5 mg/L in the nor-
mal population, and 74.5% of probable SARS pa-
tients had initial CRP values greater than the
normal level. Overall CRP values in 75% of pa-
tients reached 83.3 mg/L for those with comorbi-
dity and 34.3 mg/L for those without comorbidity.
Therefore, elevated CRP level reflects its particular
role in the pathogenesis of SARS in patients with
cardiovascular events. This study further demon-
strated that CRP levels were significantly associ-
ated with decreased RBC counts and elevated
ALT levels, indicating the coexistence of abnormal
liver function.
CRP is an excellent marker of inflammation
but lacks specificity for differentiation between
viral and bacterial infections.36,37 The mean initial
CRP value (23 mg/L) in patients with respiratory
syncytial virus (RSV) pneumonia is lower than that
in patients with pneumococcal pneumonia (145
mg/L). In mixed RSV with pneumococcal infection,
mean CRP values increased to 85 mg/L.38 Approxi-
mately 25% of SARS patients with comorbidity in
this study had plasma CRP concentrations similar
to those reported for RSV pneumonia patients. On
the other hand, Kawasaki et al observed high CRP
levels in patients with prolonged fever and strong
inflammatory response due to adenovirus respira-
tory infection.39 Patients with adenovirus respira-
tory infection have clinical features resembling
those in patients with bacterial infection.40,41 Al-
though the inability to differentiate between viral
and bacterial infection based on CRP level remains
an inherent disadvantage of this marker, this study
demonstrated a clear inflammatory response to
coronavirus infection.
The initial CRP association with SARS fatality
was apparently overlooked by most previous SARS
studies. This factor may serve as an important pre-
dictor of SARS mortality. In conclusion, SARS is a
serious respiratory illness with a high case fatality
rate in Taiwan. Reasons for the conspicuously high
case fatality of SARS patients in Taiwan remain
speculative. High initial neutrophil counts, and
plasma CRP and LDH are important early signs
for predicting death from this disease. A clear
presentation in hematological and biochemical
measurements for SARS patients may help physi-
cians to provide optimized care. Early recognition,
prompt isolation, and appropriate therapy are key
to effectively combat this deadly infection.
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